Therapy for Dupuytren’s Disease: Collagenase Therapy—A Long-Term Follow-Up Study
Collagenase therapy for Dupuytren's disease achieved significant long-term improvements in contracture in both MCP and PIP joints. In accordance with general risk factors for DD, patients with diabetes and those with nicotine abuse are at risk of worse long-term outcomes. Overall, it is a time-saving, low-risk, and straightforward technique for treating the disabling contracture component of this disease.
Authors
- Nikolaus Wachtel (ORCID: https://orcid.org/0000-0003-3746-7838)
- Nicholas Moellhoff (ORCID: https://orcid.org/0000-0002-1059-5840)
- Tim Nürnberger
- Felix H. Vollbach (ORCID: https://orcid.org/0000-0001-6522-1312)
- Wolfram Demmer (ORCID: https://orcid.org/0000-0001-7893-3976)
- Riccardo E. Giunta (ORCID: https://orcid.org/0009-0007-7421-1213)
- Francesca Romana Dingler
Institutions
- LMU Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Life
- Published
- 2024-10-08
- DOI
- https://doi.org/10.3390/life14101275
- Citations
- 1
- Primary Topic
- Dupuytren's Contracture and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.47